Share on PinterestThe FDA approved the first nonprescription sale of Dexcom’s continuous glucose monitor for children ages 2 to 18 with diabetes. Svetikd/Getty Images The Food and Drug Administration (FDA) approved the first over-the-counter continuous glucose monitor for children under 18. Experts say the over-the-counter version will make this helpful technology more widely available to […]
Read MoreIntroduction and Objective: The MiniMed™ 780G (MM780G) system (Medtronic Diabetes) integrated with the Instinct™ sensor (Abbott Diabetes Care) was recently launched in the United States (U.S.). Designed for use with MiniMed systems, the Instinct™ sensor provides another option for MM780G automated insulin delivery (AID), in addition to the Simplera Sync™ and Guardian™ 4 sensors. The […]
Read MoreIntroduction and Objective: The Inflation Reduction Act (IRA), effective January 1, 2023, capped monthly insulin costs for Medicare Part D beneficiaries at $35. Payor restrictions have created barriers to patient access on an innovative Inhaled mealtime Insulin Afrezza driven primarily by high out of pocket costs and prior authorization barriers. This IRA policy shift influenced […]
Read MoreIntroduction and Objective: Bedside clinical methods to screen diabetic peripheral neuropathy (DPN) are not reproducible and detect DPN late. In a recent study of diabetes patients, DPN was detected in 14.4% using the 10 g monofilament (10gMF), increasing to 51.5% with DPN-Check, a point-of-care device measuring sural nerve conduction velocity and amplitude. We evaluated whether […]
Read More
Share on PinterestUsing GLP-1s may increase your risk of heat-related illnesses. Image Credit: Nora Carol Photography/Getty Images GLP-1 medications may increase heat-related risks by suppressing thirst and reducing fluid intake. Thirst reduction may lead to severe dehydration and even kidney damage. GLP-1 drugs may also lower blood pressure in some people, potentially leading to other […]
Read MoreIntroduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prescription increased rapidly in Medicare for type 2 diabetes (T2D), with limited evidence on medical expenditures. We estimated expenditure changes using a matched controlled design.Methods: Using 2015-2023 Medicare fee-for-service claims, we identified beneficiaries aged ≥67 years with prevalent T2D, continuous Part A, B, and D enrollment, […]
Read MoreIntroduction and Objective: Rural populations experience higher diabetes burden and barriers to care. RDMPs may mitigate geographic barriers; however, evidence comparing rural and urban populations remains limited. The objective of this study was to evaluate whether enrollment (ENR), engagement (ENG), and glycemic outcomes among rural participants in an RDMP were non-inferior to urban participants.Methods: We […]
Read MoreIntroduction and Objective: The health and psychosocial impacts of recurrent severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia (IAH) in adults with type 1 diabetes (T1D) who use continuous glucose monitors (CGM) and insulin pumps remain poorly understood. This study describes the health and psychosocial burden of adults with T1D using CGM and insulin […]
Read MoreIntroduction and Objective: Insulin pump-based Automated Insulin Delivery (AID) therapy has significantly improved glucose control and reduced hypoglycemic risk in patients with Type 1 Diabetes (T1D), but is currently only approved to use with U-100 insulin, which can be problematic in patients with severe insulin resistance, due to frequent cartridge volume exhaustion, infusion site saturation, […]
Read MoreIntroduction and Objective: Although worsening glycemic control during the menstrual cycle (MC) has been reported in type 1 diabetes (T1D), the influence of premenstrual syndrome (PMS) remains poorly defined. Objectives: i) To characterize PMS severity across MC phases; ii) To evaluate associations between PMS severity and glycemic control, (iii) To assess whether higher PMS severity […]
Read More